+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Barrett's Esophagus: Diagnosis, Screening, Surveillance, and Controversies



Barrett's Esophagus: Diagnosis, Screening, Surveillance, and Controversies



Gut and Liver 1(2): 93-100



Barrett's esophagus (BE) is a frequent complication of gastroesophageal reflux disease, an acquired condition resulting from persistent mucosal injury to the esophagus. The incidence of Barrett's metaplasia and Barrett's adenocarcinoma has been increasing, but the prognosis of Barrett's adenocarcinoma is worse because individuals present at a late stage. Attempts have been made to intervene at early stage using surveillance programmes, although proof of efficacy of endoscopic surveillance is lacking. There is much to be learned about BE. Whether adequate control of gastroesophageal reflux early in the disease alters the natural history of Barrett's change once it has developed remains unanswered. Thus there is great need for carefully designed large randomised controlled trials to address these issues in order to determine how best to manage patients with BE. The AspECT and BOSS clinical trials proride this basis.

(PDF emailed within 1 workday: $29.90)

Accession: 051756057

Download citation: RISBibTeXText

PMID: 20485625


Related references

Controversies in the diagnosis of Barrett esophagus and Barrett-related dysplasia: one pathologist's perspective. Archives of Pathology and Laboratory Medicine 134(10): 1479-1484, 2010

Mo1922 Adherence to the 2011 AGA Medical Position Statement for the Diagnosis, Screening, and Surveillance of Barrett's Esophagus. Gastroenterology 144(5): S-694-S-695, 2013

How far to go? Screening and surveillance in Barrett's esophagus. American Journal of Managed Care 7(1 Suppl): S19-S26, 2001

Screening and surveillance of Barrett's esophagus. Current Gastroenterology Reports 11(3): 195-201, 2009

Screening and surveillance for Barrett esophagus. JAMA Internal Medicine 175(2): 159-160, 2015

Screening for and surveillance of Barrett's esophagus is clinically indicated. Digestive Diseases 25(3): 197-202, 2007

Surveillance and screening for Barrett esophagus and adenocarcinoma. Journal of Clinical Gastroenterology 39(4 Suppl 2): S33-S41, 2005

Barrett's esophagus: novel strategies for screening and surveillance. Therapeutic Advances in Chronic Disease 10: 2040622319837851, 2019

Not all of Barrett's esophagus surveillance protocols are created equal: the dangers of retrospective outcome research in the treatment of Barrett's esophagus. Gastrointestinal Endoscopy 80(6): 1203, 2015

The field effect in Barrett's esophagus: can we use it for screening and surveillance?. Endoscopy 45(12): 989-991, 2014

Evolving screening and surveillance techniques for Barrett's esophagus. World Journal of Gastroenterology 25(17): 2045-2057, 2019

Screening and surveillance in Barrett's esophagus: a call to action. Clinical Gastroenterology and Hepatology 2(10): 861-864, 2004

Barrett's esophagus: update on screening, surveillance, and treatment. Archives of Internal Medicine 159(13): 1411-1416, 1999

Screening and Surveillance for Barrett's Esophagus: Is It Cost-Effective?. Digestive Diseases and Sciences 63(8): 2094-2104, 2018

Critical appraisal of guidelines for screening and surveillance of Barrett's esophagus. Annals of Translational Medicine 6(13): 259, 2018